BIOTRONIK Announces Full Release of CardioMessenger Smart 3G in Japan

Sleek Device Together with Home Monitoring Allows for Earlier Therapy Adjustments in Cardiovascular Implantable Electronic Device Patients

TOKYO, Japan, May 21, 2015 – BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced today the full launch of CardioMessenger® Smart 3G in Japan. The portable data-transmitter device is about the size of a smartphone. It keeps pacemaker and implantable cardioverter defibrillator (ICD) wearers connected to their physicians, enabling safer, more efficient treatment at any time, nearly anywhere in the world. Japan is the first country to introduce the new transmitter and it will be rolled out in European countries throughout 2015.

Conventional remote monitoring systems in Japan require an AC adapter, so taking the transmitter outside is not possible. Because of this, data is usually only transmitted when the patient is at home. With CardioMessenger Smart 3G, equipped with a rechargeable internal battery, patients can carry the transmitter anywhere and anytime, just like a mobile phone. It enables continuous daily monitoring, independent of the patient’s lifestyle. Data can be transmitted to the physician via BIOTRONIK Home Monitoring®, even if the patient is in a place without an AC adaptor when they develop arrhythmic events. As demonstrated by the IN-TIME1 trial, Home Monitoring significantly reduces mortality rates.

“I believe that CardioMessenger Smart 3G will improve the therapeutic quality as it increases prompt reactions by physicians,” commented Dr. Eiichi Watanabe, Professor at the Department of Cardiology Fujita Health University School of Medicine. “In addition, it’s very comforting to patients who feel that they are always taken care of when they carry their CardioMessenger Smart 3G,” added Dr. Watanabe, who was the principal investigator for the Japanese Home ICD study. This study evaluated the reliability of ICD Home Monitoring in forecasting the need for regular office visits and patient perspective. Judged by an independent committee, the study found that remote monitoring correctly forecasted 75.1 percent of non-necessity remote follow-ups and 94.5 percent of the patient population were comfortable with the technology2.

CardioMessenger Smart 3G sends information from the device to the BIOTRONIK Home Monitoring Service Center using wireless RF2 telemetry and coded data transmission for maximum safety and security. Consistent and reliable data transmission occurs both daily and when triggered by an event. A call back message for patients enables physicians to get in contact with their patients whenever necessary.

“More than 10,000 Japanese hearts are already safely taken care of with BIOTROINIK Home Monitoring,” commented Jeffrey Annis, Managing Director BIOTRONIK Japan. “With the launch of the CardioMessenger Smart in Japan, more patients will have the peace of mind knowing that they can take this technology with them at anytime and anywhere,”

  1. Hindricks G et al. The Lancet. 2014, 384(9943).
  2. Watanabe et al. Circulation J2013; 77: 2704-2711.


BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries.